62nd MEETING. New MRLs Annex I Annex II Opinions adopted at this 2 1 meeting. Old MRLs 1 Annex I Annex II Extension of provisional MRLs

Transcription

1 The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology London, 11th January 2001 PRESS RELEASE COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS 62nd MEETING The Committee elected S. Dean as Chairman and G. Moulin as Vice-Chairman for the term CVMP Opinions The Committee unanimously adopted a positive opinion and CVMP assessment report for an to a non-steroidal anti-inflammatory drug (NSAID) product falling under Part B of the Annex to Council Regulation (EEC) No. 2309/93. The provides for an additional indication for use in reducing clinical signs of diarrhoea when used in combination with oral re-hydration therapy in young calves over one week of age and young non-lactating cattle. New MRLs Annex I Annex II Opinions adopted at this 2 1 meeting The Committee considered an appeal in respect of a MRL opinion for one substance and upheld the previous decision not to recommend the establishment of final MRLs. Old MRLs 1 Annex I Annex II Extension of provisional MRLs Opinions adopted at this meeting 1 Substances with provisional MRLs Negative opinion/no recommendation Opinions delivered since Applications under evaluation Applications anticipated within the next 4 months Centralised procedures New MRL procedures Applications submitted to the EMEA after Including 14 Opinions recommending definitive MRLs for substances with previously provisional MRLs Guidelines, SOPs and Position Papers Public 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) Fax (44-20) mail@emea.eudra.org

2 The Committee continues in its endeavours to agree a common TSE Note for Guidance, with the CPMP, recognising the specific requirements for veterinary medicines intended for ruminants, which it anticipates will be finalised and released after adoption by both Committees by February The Committee adopted the following revised Notes for Guidance: Guidelines for the conduct of bioequivalence studies for veterinary medicinal products (/016/00-FINAL) Note for guidance on Risk Analysis Approach for Residues of Veterinary Medicinal Products in Food of Animal Origin (/187/00-FINAL) The Committee adopted the following SOPs: Compliance with Article 28(2) of Council Regulation No 2309/93 (/036/97- REVISION) Compliance with Article 28(4) of Council Regulation (EEC) No 2309/93 (/037/97- REVISON) The next meeting of the CVMP will be held on February Peter G.H. Jones Head, Veterinary Medicines Evaluation Unit This press release and other documents are available on the Internet at the following address: CVMP Press Release January nd meeting Page 2/6

3 Maximum Residue Limits for New Substances adopted by the Community since January 2000 Substance a) INN a) Bismuth subnitrate a) Acetyl isovaleryl tylosin tartrate a) Bovine a) days a) Porcine a) days d) 1260 days a) Methylprednisolone a) Bovine a) c) 92 days a) Deltamethrin a) Tylosin a) Fin fish a) a) Eggs a) a) Dicyclanil a) Ovine a) days d) 825 days a) Tilmicosin a) Flumequine a) Tiamulin a) Dicyclanil (modification) a) Butafosfan a) Tilmicosin a) Phoxim a) Rabbit a) c) 86 days a) Bovine milk & turkey a) c) 89 days a) Rabbit a) b) a) Sheep fat a) b) c) 84 days a) Dairy cattle a) a) Bovine milk a) days d) 210 days a) Ovine a) a) Sent to b) Date of the regulation c) OJ No. b) c) OJ No. L 145 of b) c) OJ No. L 145 of b) c) OJ No. L 145 of c) OJ No. L234 of c) OJ No. L234 of c) OJ No. L234 of b) c) OJ No. L269 of a) b) c) OJ No. L269 of a) b) c) OJ No. L269 of a) CVMP Press Release January nd meeting Page 3/6

4 Substance a) INN a) Phoxim a) Flumethrin a) Flunixin a) Toltrazuril a) Ovine a) a) Ovine a) a) Equidae a) a) Porcine a) days d) 284 days a) Halofuginone a) Bovine a) days d) 1008 days a) Difloxacin a) Bovine, Porcine a) days d) 503 days a) Sent to b) Date of the regulation c) OJ No. Maximum Residue Limits for Old Substances adopted by the CVMP and the Community Status: January 2001 TOTAL 577 Annex I Annex II Annex III Annex IV Published in the Official Journal of the European Communities: 535 CVMP Press Release January nd meeting Page 4/6

5 Veterinary Medicinal Products that have been granted a Community marketing authorisation since January 2000 Product a) Brandname b) INN /B a) Ibraxion b) Inactivated vaccine a) Metacam b) Meloxicam a) Metacam b) Meloxicam a) Incurin b) Oestriol a) Rabigen SAG2 b) Live vaccine a) Eurifel FeLV b) Live vaccine a) Porcilis Pesti b) Inactivated vaccine a) Ibaflin b) Ibafloxacin a) Metacam b) Meloxicam c)part B Company a) Name b) Origin a) Merial a) Boehringer Ingelheim b) DE a) Boehringer Ingelheim b) DE a) Virbac a) Merial a) Boehringer Ingelheim b) DE b) Indication a) Cattle IBR b) Alleviation of pain and inflammation b) Initiation therapy for alleviation of pain and inflammation b) Hormonedependent urinary incontinence a) Foxes rabies a) Cats feline leukaemis b) Marker vaccine against CSF b) Pyoderma b) Post-operative pain Presentation a) Form b) Dosage c) No. of presentations a) Emulsion for a) Oral suspension b) 1.5 mg/ml a) Solution for b) 5 mg/ml a) Scored tablets b) 1 mg a) Liquid within a blister pack embeddedina bait b) 8 log 10 CCID50 a) Pellet + diluent b) 1 ml a) Water in oil emulsion b) 120 Elisa Units/2ml a) Tablet b) 150 & 300mg a) Solution for b) 5mg/ml a) d) 176 days d) 92 days d) 92 days a) b) d) 302 days a) b) days d) 428 days b) days d) 120 days a) d) 246 days b) d) 184 days a) days d) 7 days a) Opinion received b) Decision c) Notification d) OJ No. a) b) d) OJ No. C 95 of a) b) a) b) a) b) a) b) a) b) b) d) OJ No. C 183 of a) b) d) OJ No. C 183 of a) d) OJ No. C 277 of CVMP Press Release January nd meeting Page 5/6

6 Product a) Brandname b) INN /B a) Econor b) Valnemulin a) Econor b) Valnemulin a) Econor b) Valnemulin a) Dicural b) Difloxacin a) Porcilis AR-T- DF b) Inactivated vaccine a) Poulflox b) Difloxacin a) Pruban b) Resocortol butyrate Company a) Name b) Origin a) Novartis b) AT a) Novartis b) AT a) Novartis b) AT a) Fort Dodge Animal Health a) Virbac S.A. b) Indication b) Prevention & treatment of dysentery b) Prevention /treatment of dysentery and treatment/control of enzootic pneumonia b) Prevention /treatment of dysentery and treatment/control of enzootic pneumonia a) Cattle & Dogs b) Antibacterial for systemic use atrophic rhinitis a) Poultry b) Antibacterial for systemic use b) Antiinflammatory for cutaneous inflammatory disorders Presentation a) Form b) Dosage c) No. of presentations a) 0.5% premix b) various a) 10%/50% premix b) various a) 10%/50% premix b) various a) Solution for b) 50 mg/ml a) Suspension for b) 2 ml a) Oral solution b) 100 mg/ml a) Cream b) 1 mg/ml a) d) 43 days a) days a) days a) days d) 351 days b) days d) 336 days a) days d) 43 days a) b) days d) 477 days a) Opinion received b) Decision c) Notification d) OJ No d) OJ No. C 308 of d) OJ No. C 308 of d) OJ No. C 308 of b) d) OJ No. C 337 of a) b) d) OJ No. C 2 of b) d) OJ No. C 2 of a) b) d) OJ No. C 2 of Further information is available on Maximum Residue Limits adopted by the Community and Veterinary Medicinal Products that have been granted a Community Marketing Authorisation in the EMEA General Report 1999 on the Internet at the following address: CVMP Press Release January nd meeting Page 6/6